Compare Novavax Inc (NVAX) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Novavax Inc trades at $12.59 (market cap $1.82B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.74 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 13.9× Novavax Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NVAX | RPRX | |
|---|---|---|
Market Cap | $1.82B | $25.27B |
Volume | 6,198,505 | 3,671,183 |
Sector | Health | Health |
52-Week High | $12.56 | $63.96 |
52-Week Low | $6.22 | $35.44 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.39B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
